China SXT Pharmaceuticals, Inc.
SXTC
$2.86
$0.3714.86%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.78% | 1.97% | -2.18% | -23.62% | -38.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.78% | 1.97% | -2.18% | -23.62% | -38.80% |
| Cost of Revenue | 31.54% | 6.44% | -11.07% | -25.93% | -38.94% |
| Gross Profit | -35.94% | -9.21% | 29.99% | -18.32% | -38.56% |
| SG&A Expenses | -144.16% | -118.07% | -53.44% | 64.80% | 215.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -131.66% | -103.48% | -44.39% | 42.48% | 143.27% |
| Operating Income | 149.18% | 124.19% | 60.21% | -78.59% | -290.20% |
| Income Before Tax | 140.99% | 113.43% | 47.79% | -71.13% | -241.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 140.99% | 113.43% | 47.79% | -71.09% | -241.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 140.99% | 113.43% | 47.79% | -71.09% | -241.56% |
| EBIT | 149.18% | 124.19% | 60.21% | -78.59% | -290.20% |
| EBITDA | 151.37% | 126.88% | 62.28% | -83.90% | -312.33% |
| EPS Basic | 117.22% | 83.70% | 43.82% | -10.40% | -102.79% |
| Normalized Basic EPS | 118.89% | 84.50% | 43.35% | -9.73% | -97.25% |
| EPS Diluted | 117.22% | 83.70% | 43.82% | -10.40% | -102.79% |
| Normalized Diluted EPS | 118.89% | 84.50% | 43.35% | -9.73% | -97.25% |
| Average Basic Shares Outstanding | 378.23% | 322.34% | 224.70% | 319.10% | 811.72% |
| Average Diluted Shares Outstanding | 378.23% | 322.34% | 224.70% | 319.10% | 811.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
